Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients

• Main Author: Ulrich Julius
• Format: Article
• Language: English
• Published: MDPI AG 2018-05-01
• Series: Journal of Cardiovascular Development and Disease
• Subjects: LDL-cholesterol; lipoprotein(a); triglycerides; cardiovascular events; lipoprotein apheresis; PCSK9 inhibitors; lomitapide; antisense oligonucleotide against apolipoprotein(a)
• Online Access: http://www.mdpi.com/2308-3425/5/2/27

Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared not to be effective enough. Homozygous familial hypercholesterolemia represents a clear indication to start LA therapy. Another recognized indication is a severe hypercholesterolemia, which induced CVE, often in association with other risk factors. In the last years, an expressive elevation of lipoprotein(a) (Lp(a)) emerged as an indication for LA. In Germany, progress of atherosclerosis should have been documented before the permission to start LA therapy is given in these patients. Usually, all LA methods acutely decrease both LDL-C and Lp(a). However, specific columns which reduce only Lp(a) are available. Case reports and prospective observations comparing the situation before and during LA therapy clearly show a high efficiency with respect to the reduction of CVE, especially in patients with high Lp(a) levels. PCSK9 inhibitors may reduce the need for LA in patients with heterozygous or polygenetic hypercholesterolemia, but in some patients, a combination of these drugs with LA will be necessary. In the future, an antisense oligonucleotide against apolipoprotein(a) may offer an alternative therapeutic approach.